Immunome Inc (IMNM)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Immunome Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 22.80 $ — 77% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 1.6% failed
- More than 10% revenue growth is expected for the coming year 2,379.2% passed
- Share count grows by less than 3% a year 93.1% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -2,913.4% failed
- Gross margin at 40% or higher and without meaningful erosion 57.4% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 650 m net cash passed
- Operating cash flow covers the profits of the last three years 303 m failed
- Return on capital at 15% or higher, or up versus two years ago -33.6% failed
- Insiders hold at least 10% or are net buyers 6.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 56.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.12 | -2.45 – -1.84 | 3 | 12.6% | 12 |
| 12/31/2027 | -2.12 | -2.71 – -1.71 | 65 | 0.2% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.51 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.28 | – | 3 | -28.40 | -2,930.90 | -42 | -43 |
| 2025: Q1 | -0.52 | – | 3 | 184.40 | -1,423.10 | -53 | -57 |
| 2025: Q2 | -0.50 | – | 4 | 69.80 | -1,080.90 | -49 | -50 |
| 2025: Q3 | -0.65 | – | 0 | -100.00 | – | -41 | -42 |
| 2025: Q4 | -0.80 | – | 0 | -100.00 | – | -48 | -52 |
| 2026: Q1 | -0.48 | – | 0 | -100.00 | – | -59 | -62 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 0 | -8 | -8 | -7.18 | -7 | -25 | 4 |
| 2019 | 0 | -10 | -11 | -1.84 | -10 | -36 | 5 |
| 2020 | 0 | -12 | -17 | -1.69 | -12 | 41 | 45 |
| 2021 | 0 | -25 | -25 | -2.14 | -18 | 48 | 58 |
| 2022 | 7 | -37 | -37 | -3.04 | -29 | 17 | 24 |
| 2023 | 14 | -110 | -107 | -5.38 | -8 | 120 | 149 |
| 2024 | 9 | -306 | -293 | -5.00 | -111 | 181 | 240 |
| 2025 | 7 | -214 | -212 | -2.43 | -191 | 634 | 683 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Immunome, Inc., ein Biotechnologieunternehmen, befasst sich mit Entdeckung, Design, Entwicklung, Herstellung und Vermarktung von Antikörper-Wirkstoff-Konjugaten und anderen onkologischen Therapeutika in den USA.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 206 |
| Headquarters | Bothell, WA |
| Address | 18702 North Creek Parkway, 98011 Bothell, United States |
| Phone | 425 939 7410 |
| Website | immunome.com |
| IPO Date | 2. Oct 2020 |
| ISIN | US45257U1088 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Clay B. Siegall Ph.D. | Chairman, President & CEO | 1961 |
| Max Rosett | Chief Financial Officer | 1990 |
| Robert J. Lechleider M.D. | Chief Medical Officer | 1961 |
| Philip Tsai | Chief Technical Officer | 1968 |
| Jack Higgins Ph.D. | Chief Scientific Officer | 1980 |
| Sandra G. Stoneman Esq., J.D. | Chief Legal Officer, General Counsel & Corporate Secretary | 1973 |
| Kinney Horn | Chief Business Officer | 1975 |
| Roee Shahar | Executive Vice President of Commercial | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 23. Jul 2026 | Tsai Philip | Chief Technical Officer | Other | 38,250 | 0.00 | – |
| 23. Jul 2026 | Lechleider Robert | Chief Medical Officer | Other | 54,000 | 0.00 | – |
| 23. Jul 2026 | Rosett Max | Chief Financial Officer | Other | 47,250 | 0.00 | – |
| 23. Jul 2026 | Higgins Jack | Chief Scientific Officer | Other | 38,250 | 0.00 | – |
| 23. Jul 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Other | 31,250 | 0.00 | – |
| 23. Jul 2026 | Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | Other | 38,250 | 0.00 | – |
| 23. Jul 2026 | Siegall Clay B | President and CEO | Other | 180,000 | 0.00 | – |
| 7. Jul 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Sell | 1,092 | 25.00 | 27,300 |
| 7. Jul 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | Other | 1,092 | 12.92 | 14,109 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.